full-dose ritonavir (600 mg bid), protease inhibitors administered
without ritonavir, and other NNRTIs.
-- INTELENCE should not be co-administered with carbamazepine,
phenobarbital, phenytoin, rifampin, rifapentine, rifabutin (when part
of a regimen containing protease inhibitor/ritonavir) or products
containing St. John's wort (Hypericum perforatum).
-- INTELENCE and lopinavir/ritonavir should be co-administered with
-- Coadministration of INTELENCE with other agents such as
substrates, inhibitors, or inducers of CYP3A4, CYP2C9, and/or CYP2C19
may alter the therapeutic effect or adverse events profile of INTELENCE
or the co-administered drug(s). This is not a complete list of
potential drug interactions.
Please see full Prescribing Information for more details, available at http://www.INTELENCE-info.com.
Patient Access to INTELENCE
INTELENCE is expected to be available at the wholesale level in the U.S. within one week.
Martin Delaney of the Fair Pricing Coalition said, "Tibotec Therapeutics continues to demonstrate real leadership in the pharmaceutical industry by pricing INTELENCE fairly and responsibly. We applaud Tibotec's responsible corporate behavior and expect to see the drug quickly accepted on all formularies."
"With the introduction of INTELENCE, Tibotec Therapeutics has demonstrated exceptional leadership in working with the HIV community in an effort to address pricing and access issues. Tibotec has repeatedly recognized the necessity of responsibly pricing HIV products and should be commended for its leadership in this regard," said Lynda Dee from the AIDS Treatment Activist Coalition.
Tibotec Therapeutics, a division of Ortho Biotech Products, L.P.,
headquartered in Bridgewater, N.J., is dedicated to deliver
|SOURCE Tibotec Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved